Certara, Inc. (NASDAQ:CERT) Receives $17.79 Average PT from Analysts

Shares of Certara, Inc. (NASDAQ:CERT) have earned an average rating of “Hold” from the nine analysts that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $17.79.

CERT has been the topic of several recent analyst reports. JMP Securities reiterated a “market perform” rating on shares of Certara in a report on Wednesday, July 10th. Robert W. Baird cut their price target on shares of Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Barclays lowered their price objective on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday, June 28th. KeyCorp cut their price objective on shares of Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Finally, UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a report on Friday.

Certara Stock Up 9.8 %

Certara stock opened at $11.75 on Friday. The company’s 50 day simple moving average is $12.73 and its 200 day simple moving average is $15.08. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.61 and a quick ratio of 2.61. The firm has a market capitalization of $1.89 billion, a price-to-earnings ratio of -30.13, a PEG ratio of 5.17 and a beta of 1.49. Certara has a fifty-two week low of $10.35 and a fifty-two week high of $19.87.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The firm had revenue of $93.31 million during the quarter, compared to the consensus estimate of $96.01 million. Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. Certara’s quarterly revenue was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 EPS. As a group, sell-side analysts anticipate that Certara will post 0.27 EPS for the current year.

Insiders Place Their Bets

In other news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the sale, the insider now owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 2.39% of the company’s stock.

Hedge Funds Weigh In On Certara

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Algert Global LLC bought a new position in shares of Certara during the 2nd quarter worth approximately $156,000. Select Equity Group L.P. boosted its position in Certara by 19.6% during the second quarter. Select Equity Group L.P. now owns 159,008 shares of the company’s stock worth $2,202,000 after purchasing an additional 26,095 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Certara by 4.5% in the second quarter. The Manufacturers Life Insurance Company now owns 22,871 shares of the company’s stock valued at $317,000 after purchasing an additional 975 shares during the last quarter. Daventry Group LP raised its position in shares of Certara by 153.0% in the second quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock valued at $18,124,000 after purchasing an additional 791,405 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in shares of Certara during the 2nd quarter worth about $311,000. Institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.